Low-dose diethystilbestrol in treatment of men with CRPC

It has been a long time since we saw any truly new data on the efficacy and safety of a very old form of hormonal therapy (diethylstilbestrol or DES) in the treatment of advanced prostate cancer. … READ MORE …

Guidelines and the current treatment of mCRPC

The December 1 issue of The ASCO Post contains two articles that will be of interest to many patients with progressive disease and their family members. … READ MORE …

Innocrin Pharmaceuticals moving VT-464 into Phase II portion of Phase I/II trial

Innocrin Pharmaceuticals has been conducting the Phase I portion of a Phase I /II trial of VT-464, a CYP17 lyase inhibitor, in men with treatment-naïve CRPC and in CRPC patients who have failed prior therapy with abiraterone, enzalutamide, and/or chemotherapy. … READ MORE …

Who’s actually dying of prostate cancer (in France) today?

A newly published paper from a French research group has provided some interesting data on which patients actually die of prostate cancer in the modern, post-PSA era. … READ MORE …

Cabozantinib not sufficiently effective in treatment of mCRPC

According to a media release from Exelixis in the past hour, it appears that we have seen the end of all attempts to develop cabozantinib as a treatment for metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Can galeterone show effectiveness in men with AR-V7 mCRPC?

According to a report in The ASCO Post last night, the investigational drug galeterone may have significant clinical activity against a specific subtype of castration-resistant prostate cancer (CRPC) known as AR-V7. … READ MORE …

Combination immunotherapy for men with mCRPC: another new trial proposed

Late yesterday, Advaxis Immunotherapies announced the potential initiation of human trials of another new form of immunotherapy for the treatment of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,186 other followers